Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury
TH Sisson, PJ Christensen, Y Muraki… - Physiological …, 2018 - Wiley Online Library
Fibrosis of the lung constitutes a major clinical challenge and novel therapies are required to
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury
TH Sisson, PJ Christensen, Y Muraki, AJ Dils… - 2018 - deepblue.lib.umich.edu
Fibrosis of the lung constitutes a major clinical challenge and novel therapies are required to
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury
TH Sisson, PJ Christensen, Y Muraki… - Physiological …, 2018 - ohiostate.elsevierpure.com
Fibrosis of the lung constitutes a major clinical challenge and novel therapies are required to
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury
TH Sisson, PJ Christensen, Y Muraki… - Physiological …, 2018 - pubmed.ncbi.nlm.nih.gov
Fibrosis of the lung constitutes a major clinical challenge and novel therapies are required to
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
TH Sisson, PJ Christensen, Y Muraki, AJ Dils… - Physiological …, 2018 - europepmc.org
Fibrosis of the lung constitutes a major clinical challenge and novel therapies are required to
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
TH Sisson, PJ Christensen, Y Muraki, AJ Dils… - Physiological …, 2018 - go.gale.com
Fibrosis of the lung constitutes a major clinical challenge and novel therapies are required to
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
[HTML][HTML] Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury
TH Sisson, PJ Christensen, Y Muraki, AJ Dils… - Physiological …, 2018 - ncbi.nlm.nih.gov
Fibrosis of the lung constitutes a major clinical challenge and novel therapies are required to
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
TH Sisson, PJ Christensen, Y Muraki, AJ Dils… - Physiological …, 2018 - europepmc.org
Fibrosis of the lung constitutes a major clinical challenge and novel therapies are required to
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …
alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs …